View ValuationWonbiogen 将来の成長Future 基準チェック /06現在、 Wonbiogenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長44.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩6,100, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total loss to shareholders of 39% over the past three years.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩7,800, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 12% over the past three years.お知らせ • Mar 17Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2026Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 56, 1gongdan-ro 5-gil, gyeongsangbuk-do, gumi South KoreaValuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,100, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 7.4% over the past three years.分析記事 • Feb 07Wonbiogen Co., Ltd. (KOSDAQ:307280) Shares Fly 27% But Investors Aren't Buying For GrowthWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shares have continued their recent momentum with a 27% gain in the last month...分析記事 • Feb 05Here's Why We Think Wonbiogen (KOSDAQ:307280) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Dec 09Wonbiogen (KOSDAQ:307280) Has Affirmed Its Dividend Of ₩20.00The board of Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) has announced that it will pay a dividend on the 15th of April, with...お知らせ • Dec 09Wonbiogen Co., Ltd. (KOSDAQ:A307280) announces an Equity Buyback for KRW 2,000 million worth of its shares.Wonbiogen Co., Ltd. (KOSDAQ:A307280) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares according to the contract with NH Investment & Securities. The purpose of the program is stock price stability and shareholder value reconsideration. The program will expire on June 9, 2026. As of December 7, 2025, the company had 0 shares in treasury within scope available for dividend and had 1,375 shares under other acquisitions.分析記事 • Dec 04Wonbiogen Co., Ltd.'s (KOSDAQ:307280) Shares Bounce 28% But Its Business Still Trails The MarketWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shares have had a really impressive month, gaining 28% after a shaky period...Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩307 (vs ₩199 in 3Q 2024)Third quarter 2025 results: EPS: ₩307 (up from ₩199 in 3Q 2024). Revenue: ₩9.22b (up 34% from 3Q 2024). Net income: ₩2.18b (up 54% from 3Q 2024). Profit margin: 24% (up from 21% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.分析記事 • Nov 09Wonbiogen (KOSDAQ:307280) Is Due To Pay A Dividend Of ₩20.00The board of Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) has announced that it will pay a dividend on the 15th of April, with...Declared Dividend • Nov 08Dividend of ₩20.00 announcedShareholders will receive a dividend of ₩20.00. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is well covered by both earnings (12% earnings payout ratio) and cash flows (10% cash payout ratio). The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 74% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07Wonbiogen Co., Ltd. announces Annual dividend, payable on April 15, 2026Wonbiogen Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩226 (vs ₩231 in 2Q 2024)Second quarter 2025 results: EPS: ₩226 (down from ₩231 in 2Q 2024). Revenue: ₩8.40b (up 5.0% from 2Q 2024). Net income: ₩1.60b (down 2.1% from 2Q 2024). Profit margin: 19% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.分析記事 • May 26With EPS Growth And More, Wonbiogen (KOSDAQ:307280) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...分析記事 • May 26Wonbiogen Co., Ltd.'s (KOSDAQ:307280) P/E Is Still On The Mark Following 411% Share Price BounceWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shareholders have had their patience rewarded with a 411% share price jump in the...New Risk • May 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 58% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Mar 18Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2025Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: seminar room, 56, 1gongdan-ro 5-gil, gyeongsangbuk-do, gumi South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.3b market cap, or US$28.8m).Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩1,165, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total loss to shareholders of 42% over the past three years.分析記事 • Dec 09Lacklustre Performance Is Driving Wonbiogen Co., Ltd.'s (KOSDAQ:307280) 26% Price DropThe Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) share price has fared very poorly over the last month, falling by a...Reported Earnings • Nov 13Third quarter 2024 earnings released: EPS: ₩40.00 (vs ₩16.00 in 3Q 2023)Third quarter 2024 results: EPS: ₩40.00 (up from ₩16.00 in 3Q 2023). Revenue: ₩6.86b (down 1.3% from 3Q 2023). Net income: ₩1.42b (up 146% from 3Q 2023). Profit margin: 21% (up from 8.3% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.分析記事 • Nov 13We Like These Underlying Return On Capital Trends At Wonbiogen (KOSDAQ:307280)If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...New Risk • Apr 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Continuous dividend paying years: 1 Dividend yield: 1.1% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Market cap is less than US$100m (₩65.7b market cap, or US$48.7m).Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩157 (vs ₩90.00 in FY 2022)Full year 2023 results: EPS: ₩157 (up from ₩90.00 in FY 2022). Revenue: ₩29.6b (up 11% from FY 2022). Net income: ₩5.50b (up 72% from FY 2022). Profit margin: 19% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩1,931, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 13% over the past three years.分析記事 • Mar 13Is Wonbiogen (KOSDAQ:307280) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.6% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 8.1% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: ₩16.00 (vs ₩42.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩16.00 (down from ₩42.00 in 3Q 2022). Revenue: ₩6.95b (up 1.6% from 3Q 2022). Net income: ₩576.2m (down 62% from 3Q 2022). Profit margin: 8.3% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in South Korea.New Risk • Oct 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩62.2b market cap, or US$46.0m).Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩2,440, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 42% over the past year.Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩41.00 (vs ₩23.00 in 1Q 2022)First quarter 2023 results: EPS: ₩41.00 (up from ₩23.00 in 1Q 2022). Revenue: ₩7.74b (up 10% from 1Q 2022). Net income: ₩1.44b (up 71% from 1Q 2022). Profit margin: 19% (up from 12% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Medical Equipment industry in South Korea.Buying Opportunity • Apr 26Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.4%. The fair value is estimated to be ₩2,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only.お知らせ • Mar 07Wonbiogen Co., Ltd. Delisted from KRXAccording to the Korea Stock Exchange (KRX), Wonbiogen Co., Ltd. has been delisted from KRX, effective from February 09, 2021. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Wonbiogen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A307280 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202636,2707,0423,3569,850N/A12/31/202535,2446,6156,4628,483N/A9/30/202534,3816,6177,0698,834N/A6/30/202532,0255,8556,9927,825N/A3/31/202531,6245,8746,8487,652N/A12/31/202430,4405,6908,1858,850N/A9/30/202429,3035,3866,6017,882N/A6/30/202429,3914,5474,4236,052N/A3/31/202428,8925,0493,6935,349N/A12/31/202329,6155,4973,1014,835N/A9/30/202327,8914,3012,9204,633N/A6/30/202327,7825,2274,2536,679N/A3/31/202327,5263,9131,0406,747N/A12/31/202226,7483,206-7865,782N/A9/30/202226,5433,455-1,7775,126N/A6/30/202224,3762,507-3,4403,308N/A3/31/202221,8682,368-1,2172,220N/A12/31/202117,721-716-1,2561,082N/A9/30/202115,390-9,681-775544N/A6/30/202114,048-9,224-899-237N/A3/31/202112,111-14,361N/AN/AN/A12/31/202012,018-11,662106798N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A307280の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A307280の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A307280の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A307280の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A307280の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A307280の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/03 22:45終値2026/08/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Wonbiogen Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Dong Gun LeeShinhan Investment Corp.Dong Gun LeeSK Securities Co., Ltd.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩6,100, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total loss to shareholders of 39% over the past three years.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩7,800, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 12% over the past three years.
お知らせ • Mar 17Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2026Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 56, 1gongdan-ro 5-gil, gyeongsangbuk-do, gumi South Korea
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,100, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 7.4% over the past three years.
分析記事 • Feb 07Wonbiogen Co., Ltd. (KOSDAQ:307280) Shares Fly 27% But Investors Aren't Buying For GrowthWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shares have continued their recent momentum with a 27% gain in the last month...
分析記事 • Feb 05Here's Why We Think Wonbiogen (KOSDAQ:307280) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Dec 09Wonbiogen (KOSDAQ:307280) Has Affirmed Its Dividend Of ₩20.00The board of Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) has announced that it will pay a dividend on the 15th of April, with...
お知らせ • Dec 09Wonbiogen Co., Ltd. (KOSDAQ:A307280) announces an Equity Buyback for KRW 2,000 million worth of its shares.Wonbiogen Co., Ltd. (KOSDAQ:A307280) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares according to the contract with NH Investment & Securities. The purpose of the program is stock price stability and shareholder value reconsideration. The program will expire on June 9, 2026. As of December 7, 2025, the company had 0 shares in treasury within scope available for dividend and had 1,375 shares under other acquisitions.
分析記事 • Dec 04Wonbiogen Co., Ltd.'s (KOSDAQ:307280) Shares Bounce 28% But Its Business Still Trails The MarketWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shares have had a really impressive month, gaining 28% after a shaky period...
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩307 (vs ₩199 in 3Q 2024)Third quarter 2025 results: EPS: ₩307 (up from ₩199 in 3Q 2024). Revenue: ₩9.22b (up 34% from 3Q 2024). Net income: ₩2.18b (up 54% from 3Q 2024). Profit margin: 24% (up from 21% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
分析記事 • Nov 09Wonbiogen (KOSDAQ:307280) Is Due To Pay A Dividend Of ₩20.00The board of Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) has announced that it will pay a dividend on the 15th of April, with...
Declared Dividend • Nov 08Dividend of ₩20.00 announcedShareholders will receive a dividend of ₩20.00. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is well covered by both earnings (12% earnings payout ratio) and cash flows (10% cash payout ratio). The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 74% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07Wonbiogen Co., Ltd. announces Annual dividend, payable on April 15, 2026Wonbiogen Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: ₩226 (vs ₩231 in 2Q 2024)Second quarter 2025 results: EPS: ₩226 (down from ₩231 in 2Q 2024). Revenue: ₩8.40b (up 5.0% from 2Q 2024). Net income: ₩1.60b (down 2.1% from 2Q 2024). Profit margin: 19% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
分析記事 • May 26With EPS Growth And More, Wonbiogen (KOSDAQ:307280) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
分析記事 • May 26Wonbiogen Co., Ltd.'s (KOSDAQ:307280) P/E Is Still On The Mark Following 411% Share Price BounceWonbiogen Co., Ltd. ( KOSDAQ:307280 ) shareholders have had their patience rewarded with a 411% share price jump in the...
New Risk • May 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 58% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Mar 18Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2025Wonbiogen Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: seminar room, 56, 1gongdan-ro 5-gil, gyeongsangbuk-do, gumi South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.3b market cap, or US$28.8m).
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩1,165, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total loss to shareholders of 42% over the past three years.
分析記事 • Dec 09Lacklustre Performance Is Driving Wonbiogen Co., Ltd.'s (KOSDAQ:307280) 26% Price DropThe Wonbiogen Co., Ltd. ( KOSDAQ:307280 ) share price has fared very poorly over the last month, falling by a...
Reported Earnings • Nov 13Third quarter 2024 earnings released: EPS: ₩40.00 (vs ₩16.00 in 3Q 2023)Third quarter 2024 results: EPS: ₩40.00 (up from ₩16.00 in 3Q 2023). Revenue: ₩6.86b (down 1.3% from 3Q 2023). Net income: ₩1.42b (up 146% from 3Q 2023). Profit margin: 21% (up from 8.3% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
分析記事 • Nov 13We Like These Underlying Return On Capital Trends At Wonbiogen (KOSDAQ:307280)If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Risk • Apr 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Continuous dividend paying years: 1 Dividend yield: 1.1% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Market cap is less than US$100m (₩65.7b market cap, or US$48.7m).
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: ₩157 (vs ₩90.00 in FY 2022)Full year 2023 results: EPS: ₩157 (up from ₩90.00 in FY 2022). Revenue: ₩29.6b (up 11% from FY 2022). Net income: ₩5.50b (up 72% from FY 2022). Profit margin: 19% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩1,931, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 13% over the past three years.
分析記事 • Mar 13Is Wonbiogen (KOSDAQ:307280) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.6% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 8.1% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).
Reported Earnings • Nov 12Third quarter 2023 earnings released: EPS: ₩16.00 (vs ₩42.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩16.00 (down from ₩42.00 in 3Q 2022). Revenue: ₩6.95b (up 1.6% from 3Q 2022). Net income: ₩576.2m (down 62% from 3Q 2022). Profit margin: 8.3% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in South Korea.
New Risk • Oct 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩62.2b market cap, or US$46.0m).
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩2,440, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 42% over the past year.
Reported Earnings • May 14First quarter 2023 earnings released: EPS: ₩41.00 (vs ₩23.00 in 1Q 2022)First quarter 2023 results: EPS: ₩41.00 (up from ₩23.00 in 1Q 2022). Revenue: ₩7.74b (up 10% from 1Q 2022). Net income: ₩1.44b (up 71% from 1Q 2022). Profit margin: 19% (up from 12% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Medical Equipment industry in South Korea.
Buying Opportunity • Apr 26Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.4%. The fair value is estimated to be ₩2,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
お知らせ • Mar 07Wonbiogen Co., Ltd. Delisted from KRXAccording to the Korea Stock Exchange (KRX), Wonbiogen Co., Ltd. has been delisted from KRX, effective from February 09, 2021.